EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, TME Pharma NV's enterprise value is €6.29 Mil.
TME Pharma NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-5.07 Mil. Therefore, TME Pharma NV's EV-to-EBITDA for today is -1.24.
The historical rank and industry rank for TME Pharma NV's EV-to-EBITDA or its related term are showing as below:
XPAR:ALTME'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.06 Med: 0.2 Max: 0.29
Current: -1.24
During the past 10 years, the highest EV-to-EBITDA of TME Pharma NV was 0.29. The lowest was -4.06. And the median was 0.20.
XPAR:ALTME's EV-to-EBITDA is ranked worse than 100% of 456
companies
in the Biotechnology industry
Industry Median: 10.52
vs XPAR:ALTME: -1.24
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
TME Pharma NV EV-to-EBITDA Historical Data
The historical data trend for TME Pharma NV's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of TME Pharma NV's EV-to-EBITDA
For the Biotechnology subindustry, TME Pharma NV's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TME Pharma NV's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TME Pharma NV's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where TME Pharma NV's EV-to-EBITDA falls into.
TME Pharma NV EV-to-EBITDA Calculation
TME Pharma NV's EV-to-EBITDA for today is calculated as:
TME Pharma NV's current Enterprise Value is €6.29 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. TME Pharma NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-5.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
TME Pharma NV's PE Ratio for today is calculated as:
TME Pharma NV's share price for today is €0.259.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. TME Pharma NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.340.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of TME Pharma NV's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product candidates are; NOX-A12 and NOX-E36 are based on a new class of drug first developed by TME Pharma called Spiegelmers, which offer specific advantages over other drug classes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XPAR:ALTME has been successfully added to your 